Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining.
about
MutS homologue hMSH5: role in cisplatin-induced DNA damage responseRegulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1.DNA repair targeted therapy: The past or future of cancer treatment?Role of autophagy in cisplatin resistance in ovarian cancer cellsThe value of FATS expression in predicting sensitivity to radiotherapy in breast cancerNovel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatinEffects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenograftsIn vivo efficacy of nano hyaluronan-conjugated cisplatin for treatment of murine melanoma.Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro.Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathwaysScintillating Nanoparticles as Energy Mediators for Enhanced Photodynamic TherapyDNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.Torin2 Suppresses Ionizing Radiation-Induced DNA Damage RepairRadiation therapy for tumors of the nasal cavity and paranasal sinuses in dogs.FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer.Sensitizing thermochemotherapy with a PARP1-inhibitor.Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies.Tongue cancers during pregnancy: Case reports and review of literature.Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy.CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-κB activation and NO production.Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.Successful local control of recurrent penile cancer treated with a combination of systemic chemotherapy, irradiation, and mohs' paste: a case report.Current advances in DNA repair: regulation of enzymes and pathways involved in maintaining genomic stability.Effect of Ku80 on the radiosensitization of cisplatin in the cervical carcinoma cell line HeLa.DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer.Metal-based NanoEnhancers for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells.Deoxyribonucleic Acid Damage and Repair: Capitalizing on Our Understanding of the Mechanisms of Maintaining Genomic Integrity for Therapeutic Purposes.Determining the Radiation Enhancement Effects of Gold Nanoparticles in Cells in a Combined Treatment with Cisplatin and Radiation at Therapeutic Megavoltage Energies.
P2860
Q24306821-A346A18A-BD25-49A1-BC39-FD38CACBA693Q24315064-CCF971A7-CC47-4507-B1B0-21A6C480D825Q26768679-D1E4E265-3083-45CD-80A3-E847A37433E1Q33761338-16E46D13-4FFE-4B72-82AF-13BEF9869BEEQ33888843-CEB462F2-4F82-42ED-B5CD-7F1C3FE601DDQ33994331-0DEC4154-41A9-4F4D-880C-D2B1FF0D5C54Q34487087-86DD5BA2-3FF1-415F-828E-8D8EE75D6337Q35130444-A54CEA4B-DD2C-4B42-9C72-8F12ED65C913Q36027858-7F689EE0-A916-4A8C-9DE2-AA5E939C1809Q36097945-BA7BB3B0-C141-47EA-A906-E24BDD4618FBQ36839885-10D87EFA-B290-48A1-AD07-4A65EE606B27Q36855596-26F7F6C1-E67E-434B-84AB-AA6D30DB5157Q37041046-CCA6B87C-F789-4585-9457-BE3C012C97E8Q37099089-714BAE6D-7586-4613-AFE6-CD1807F350C0Q37417939-B9D3F1F3-7FF5-45E7-880C-9CCF3B344B7BQ37620658-FCAFC55E-009A-4EF0-88B7-33682760906FQ37725418-60A8FF09-7715-4334-87C1-34EEB9E16B19Q37729428-52A5B3FB-19AB-491E-8C3F-C2D423E85F84Q37947198-83C14B3A-F0BE-4330-87AD-5C77B1CEA194Q38863243-A22108A3-9FCD-4965-AD35-4914EC1AF6DCQ38976861-6DF231E8-B676-460C-9050-8150D664EAEFQ39324035-020131CF-27B0-4D9A-9B07-6B68E4C24182Q39730373-5BAF28B2-B433-49A0-AE06-7CFC2D8D1D6BQ42021479-6A585DB8-C0E3-4696-9D62-17CDD08E36EEQ42735393-3D9FAA86-DC99-4F9E-8BC2-9495E601C4A0Q48521555-3889A419-9356-45BB-8772-6A08AE917240Q51611938-99EF59E6-9FC3-49EB-BF05-186B629AB859Q52647643-76FDF7B9-4C8C-4B11-99EE-E589D5182CD8Q52720061-A6F47BDE-25A4-4084-AF59-3AB3D81F82C0Q54946110-DC00F500-7EC7-4D18-8304-B89B6E811D3A
P2860
Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cisplatin sensitizes cancer ce ...... of nonhomologous end joining.
@ast
Cisplatin sensitizes cancer ce ...... of nonhomologous end joining.
@en
type
label
Cisplatin sensitizes cancer ce ...... of nonhomologous end joining.
@ast
Cisplatin sensitizes cancer ce ...... of nonhomologous end joining.
@en
prefLabel
Cisplatin sensitizes cancer ce ...... of nonhomologous end joining.
@ast
Cisplatin sensitizes cancer ce ...... of nonhomologous end joining.
@en
P2093
P2860
P1476
Cisplatin sensitizes cancer ce ...... of nonhomologous end joining.
@en
P2093
Heather J Boeckman
John J Turchi
Kelly S Trego
P2860
P304
P356
10.1158/1541-7786.MCR-04-0032
P577
2005-05-01T00:00:00Z